NYSE · BB

BlackBerry Limited

$8.42 -$0.12 (-1.41%) 1D After hours

Key Metrics

$5.01B
Market cap
P/E · TTM
Revenue · TTM
Net income
EPS · TTM
Dividend yield
Free cash flow
Beta · 1Y 1.62
EBITDA · TTM
Gross margin

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 27
    From its Jul 1 high, the share price fell 34%.

    Peak close $12.81 on Jul 1; trough close $8.42 on Jul 27. The drawdown is the fact — the chapters around it are the context.

    RECEIPT: PRICE SERIES, PEAK-TO-TROUGH -34%
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 20.3 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • Jun 25
    The stock moved +20.0% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Jun 25
  • May 22
    The stock moved +18.9% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, May 22

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap$5.01B
Enterprise value$4.79B
Shares outstanding586.1M
52-wk range$3.12 – $13.59
Avg volume · 20D14.2M
Net cash $211.90M
Book value / share$1.28
IndustryServices-Prepackaged Software
ExchangeNYSE
About BlackBerry Limited
IPO dateFeb 4, 1999
Employees1749

BlackBerry, once known for being the world's largest smartphone manufacturer, is now exclusively a software provider with a stated goal of end-to-end secure communications for enterprises.

Wolf Grade COMING SOON

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E
P/S
P/FCF
EV/EBITDA
EV/Sales
Graham №

Profitability

Gross
Operating
Net
FCF
ROE / ROIC — · —

Financial Health

Current ratio2.20
Quick ratio
Debt / equity0.26
Debt / EBITDA
Net cash $211.90M
Working capital$305.30M

Cash Flow · TTM

Operating CF
Capex
Free cash flow
Buybacks
Dividends paid
Shareholder yield

Piotroski F-Score

6 / 9
Middling fundamentals · 6 of 9 signals passing

Altman Z-Score

Insufficient balance-sheet inputs

Graham Number vs Price

Requires positive earnings and book value
Fundamentals through 2026-05-31 · computed by TickerWolf from SEC filings